Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

NCT03778073 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic/Business Decision

Conditions

B-cell Non Hodgkin Lymphoma
Richter's Transformation

Interventions

DRUG: Cosibelimab
DRUG: Cosibelimab + Ublituximab + Bendamustine combination
DRUG: Cosibelimab + Ublituximab + Bendamustine combination

Sponsor

TG Therapeutics, Inc.